A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01053988 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1031

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: FF/GW642444 Inhalation Powder
DRUG: FF Inhalation Powder
DRUG: GW642444 Inhalation Powder
DRUG: Placebo

Sponsor

GlaxoSmithKline